To evaluate human tumors, tissues, or therapies inside a living organism, preclinical research has long relied on a necessary compromise: immunodeficient animal models. By stripping away a host animal's immune defenses, researchers can successfully engraft human patient-derived xenografts (PDXs) or stem cells without the host's body immediately rejecting them as foreign objects.
However, this compromise creates a profound blind spot. As highlighted by David Andreu-Sanz et al. in Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis, the overwhelming reliance on these immunocompromised systems fails to simulate how therapies interact with a functional immune system. This lack of physiological granularity is a primary driver of the preclinical-to-clinical translation gap, explaining why therapies that look exceptionally promising in the laboratory frequently fail in human clinical trials.
The Anatomy of the Preclinical Blind Spot
When researchers use an immunodeficient model, they are not just removing a barrier to tissue engraftment; they are fundamentally altering the biological signaling environment. The nature of this blind spot depends on exactly which components of the immune system have been disabled:
- Loss of Adaptive Immunity: Common models like athymic (nude) mice lack mature T-cells. As Xiaoyan Shao et al. demonstrate in STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells, this makes it impossible to observe whether a treatment successfully triggers a systemic, long-term anti-tumor immune memory.
- Disrupted Cytokine Signaling: Many models lack functional innate pathways, such as interferon signaling. Yumin Zhang et al. note in Investigation of a clinical trial drug VV261 as a potent antiviral candidate against Chikungunya virus that this absence distorts drug metabolism and antiviral efficacy, creating discrepancies between animal data and actual human performance.
By isolating a disease from a functional immune system, these models reduce a complex, multi-cellular systemic dialogue down to a simple, isolated interaction between a drug and a target cell.
Why Efficacy Fails to Translate
The absence of a functional immune system misleads researchers in several distinct ways, obscuring both how diseases progress and how drugs actually work.
The Missing Microenvironment
Diseases do not exist in a vacuum. In Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines, Andreas Schlicker et al. emphasize that standard laboratory models omit the broader tumor microenvironment (TME), which comprises immune cells, blood vessels, and the extracellular matrix. Because the TME heavily influences how specific cancer subtypes respond to targeted therapies, omitting it masks the true mechanisms of drug sensitivity or resistance.
For example, certain proteins under investigation may not act directly on tumor cells, but instead modulate the immune cells surrounding the tumor. Ru M. Wen et al. show in AZGP1 deficiency promotes angiogenesis in prostate cancer that when researchers use immune-deficient models, they completely overlook the role of the immune system in regulating tumor progression and vessel growth, particularly for biomarkers that structurally resemble immune molecules.
Misjudging "Living Drugs" and Immunotherapies
The rise of advanced immunotherapies—such as CAR-T cells, CAR-NK cells, oncolytic viruses, and cancer vaccines—has made the limitations of immunodeficient models even more acute. These therapies are explicitly designed to interact with or leverage the host's immune architecture.
When testing these strategies in immunodeficient mice, researchers cannot accurately simulate the highly immunosuppressive macro-environment found in human patients. As Tetsuro Tachi et al. observe in Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model, this gap makes it incredibly difficult to predict whether a cellular therapy can successfully infiltrate a solid tumor and remain active. Similarly, Seong-Joon Park et al. argue in EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells that testing cancer vaccines in immunodeficient animals fails entirely to capture the intricate coordination required to activate endogenous immune defenses.
[Preclinical Testing in Immunodeficient Model]
│
├─► Lacks T/B Cells & Interferon Signaling
├─► Missing Tumor Microenvironment (TME) Dialogue
│
▼
[False Positive / Overestimated Efficacy] ──► [Clinical Trial Failure]
Overestimating Efficacy and Missing Toxicity
Without a functional immune system, preclinical experiments often yield a "clean" therapeutic effect that vanishes in patients. This occurs because immunodeficient models can cause researchers to overestimate a drug's direct cytotoxicity while missing systemic interference.
The authors of Decorin-armed oncolytic adenovirus promotes natural killers (NKs) activation and infiltration to enhance NK therapy in CRC model point out that highly immunodeficient models fail to capture how a treatment interacts with a complete host immune system, which can lead to overestimating efficacy or missing systemic immune interference that would naturally occur in a human patient.
Furthermore, these models obscure potential toxicities. When evaluating combination therapies, such as pairing a targeted inhibitor with standard chemotherapy, the lack of a functional immune environment prevents researchers from predicting whether the combination will cause severe systemic toxicity or alter immune-mediated clearance mechanisms (Juan Xiao et al., Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling).
Moving Beyond the Blind Spot
To overcome the constraints of immunodeficient models, the research direction is shifting toward experimental and computational frameworks that preserve host-immune interactions:
- Humanized Mouse Models: As reviewed by Yinxi Zhou et al. in Experimental mouse models for translational human cancer research, researchers are increasingly attempting to reconstruct a human-like immune system within immunodeficient mice by engrafting human hematopoietic stem cells. While this approach reintroduces the missing cellular dialogue, it remains technically complex and cost-prohibitive for large-scale drug screening.
- Syngeneic and Competent Modeling: For therapies where host-immune interaction is paramount, researchers are prioritizing syngeneic models (matching mouse tumors to immunocompetent mouse hosts) to ensure that the systemic immune macro-environment remains fully intact.
- Multiscale Computational Modeling: To augment physical models, researchers are leveraging mathematical and computational frameworks. By incorporating parameters for immune evasion, cytokine saturation, and cellular subpopulations, these models help simulate the complex host defenses that physical immunodeficient models leave out (Fuhai Li 0001 et al., A 3D multiscale model of cancer stem cell in tumor development).
Ultimately, understanding why immunodeficient models fail to translate is driving the development of these higher-fidelity systems, ensuring that future therapeutics are tested against the full complexity of a functional immune system before entering human trials.
Key Foundational Work
Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells (2011) — contributed 1 concept elements to this direction.
Emodin induces Panc-1 cell apoptosis via declining the mitochondrial membrane potential (2012) — contributed 1 concept elements to this direction.
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines (2012) — contributed 1 concept elements to this direction.